Monitoring global health: time for new solutions

Improved global health monitoring requires new technologies and methods, strengthened national capacity, norms and standards, and gold standard global reporting. The World Health Organization's many functions limit its capacity for global reporting, and a new global health monitoring organisation is needed to provide independent gold standard health information to the world

[1]  Alan D. Lopez,et al.  Adult mortality: time for a reappraisal. , 2004, International journal of epidemiology.

[2]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[3]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[4]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[5]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[6]  M. Raviglione.  The TB epidemic from 1992 to 2002. , 2003, Tuberculosis.

[7]  U. Dettweiler,et al.  Points to consider for ethics committees in human gene therapy trials. , 2001, Bioethics.

[8]  M Docherty,et al.  The case for structuring the discussion of scientific papers , 1999, BMJ.

[9]  R A Cash,et al.  Impediments to global surveillance of infectious diseases: consequences of open reporting in a global economy. , 2000, Bulletin of the World Health Organization.

[10]  M. Enserink.  A Global Fire Brigade Responds to Disease Outbreaks , 2004, Science.

[11]  G. Rodier,et al.  Hot spots in a wired world: WHO surveillance of emerging and re-emerging infectious diseases. , 2001, The Lancet. Infectious diseases.

[12]  N. Nevin,et al.  Gene therapy advisory committee: long-term monitoring of patients participating in gene therapy: Health Departments of the United Kingdom. , 2000, Human gene therapy.

[13]  P A Singer,et al.  Grand Challenges in Global Health , 2003, Science.

[14]  M. Bracher.  The Analysis of Maternity Histories , 1994 .

[15]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[16]  Lee Jong-wook.  Global health improvement and WHO: shaping the future , 2003, The Lancet.

[17]  Alan Cantor,et al.  The uncertainty principle and industry-sponsored research , 2000, The Lancet.

[18]  C. Murray,et al.  Validity of reported vaccination coverage in 45 countries , 2003, The Lancet.

[19]  G. Guyatt,et al.  Reviewing the reviewers: the quality of reporting in three secondary journals. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  Joshua A. Salomon,et al.  World mortality in 2000: life tables for 191 countries. , 2002 .

[21]  J. T. Boerma,et al.  Demographic and health surveys (DHS): contributions and limitations. , 1993, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[22]  P. Teirstein,et al.  Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. , 2002, The New England journal of medicine.

[23]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[24]  Michel Sadelain,et al.  Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.

[25]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[26]  Lawrence O Gostin,et al.  International infectious disease law: revision of the World Health Organization's International Health Regulations. , 2004, JAMA.

[27]  Mike Clarke,et al.  Discussion sections in reports of controlled trials published in general medical journals. , 2002, JAMA.

[28]  J. V. Cooke.  The occurrence of leukemia. , 1954, Blood.

[29]  D. Heymann,et al.  Eradicating polio. , 2004, The New England journal of medicine.

[30]  J Ties Boerma,et al.  Estimates of HIV-1 prevalence from national population-based surveys as a new gold standard , 2003, The Lancet.

[31]  A. Williams,et al.  Science or marketing at WHO? A commentary on 'World Health 2000'. , 2001, Health economics.

[32]  G A Colditz,et al.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. , 1999, JAMA.

[33]  D. Williams,et al.  Clarity and risk: the challenges of the new technologies. , 2001, Medical device technology.

[34]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[35]  K. Cornetta,et al.  American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[37]  Alan D. Lopez,et al.  Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study , 1996, Science.

[38]  A. Blanc.  Demographic and health surveys , 1991 .

[39]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[40]  N. King.  Accident & desire. Inadvertent germline effects in clinical research. , 2003, The Hastings Center report.

[41]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[42]  N. King.  Defining and Describing Benefit Appropriately in Clinical Trials , 2000, Journal of Law, Medicine & Ethics.

[43]  Paul S Appelbaum,et al.  The Therapeutic Misconception: Problems and Solutions , 2002, Medical care.

[44]  E. Marshall.  Gene therapy. Viral vectors still pack surprises. , 2001, Science.

[45]  E. Bos.  Population and Health in Developing Countries. Volume 1, Population, Health, and Survival at INDEPTH Sites. INDEPTH Network. Ottawa: International Development Research Centre, 2002, pp. 356, (PB) $40.40 ISBN: 0-88936-948-8. , 2004 .

[46]  C. Grady,et al.  What makes clinical research ethical? , 2000, JAMA.

[47]  Malcolm Segall,et al.  Methodological concerns and recommendations on policy consequences of the World Health Report 2000 , 2001, The Lancet.

[48]  J. Trussell,et al.  The Analysis of Maternity Histories. , 1992 .

[49]  Christian Gluud,et al.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? , 2003, JAMA.

[50]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[51]  S. Welin.  Starting clinical trials of xenotransplantation—reflections on the ethics of the early phase , 2000, Journal of medical ethics.

[52]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[53]  Lawrence O. Gostin.  International infectious disease law. , 2004 .

[54]  E. Marshall.  Viral Vectors Still Pack Surprises , 2001, Science.

[55]  J. Kimmelman.  Protection at the cutting edge: the case for central review of human gene transfer research. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[56]  G. Guyatt,et al.  Colloid Use for Fluid Resuscitation: Evidence and Spin , 2001, Annals of Internal Medicine.

[57]  Christof von Kalle,et al.  Side effects of retroviral gene transfer into hematopoietic stem cells. , 2003, Blood.